MBX Biosciences filed an S-1 on September 22, 2025 for 10,000,000 shares. The deal priced on September 24 at $18.00 for 11,108,055 shares and closed on September 26 with net proceeds of about $187.5 million.
Latest MBX Biosciences news
We have not published a story on MBX Biosciences yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $54.1 million, plus short-term investments of $364.5 million, $418.6 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about MBX Biosciences
Has MBX Biosciences raised money recently?
Our latest story on this, dated Sep 22, 2025: "MBX Biosciences files for 10,000,000-share offering, later sells 11,108,055 at $18.00". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of MBX Biosciences?
MBX Biosciences, Inc. trades under the ticker MBX on NASDAQ.
Where is MBX Biosciences listed?
MBX Biosciences, Inc. is listed on NASDAQ.
What is the SEC CIK of MBX Biosciences?
The SEC Central Index Key (CIK) for MBX Biosciences, Inc. is 1776111. Its filings are on SEC EDGAR.
How many shares does MBX Biosciences have outstanding?
48,160,096 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is MBX Biosciences listed under?
Our directory records MBX Biosciences, Inc. under United States.
What does MBX Biosciences do?
Our directory classifies MBX Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of MBX Biosciences?
The ISIN recorded for MBX Biosciences, Inc. is US55287L1017.
Does aibio.space cover MBX Biosciences?
aibio.space lists MBX Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is MBX Biosciences incorporated?
SEC records list its state or country of incorporation as DE.
Is MBX Biosciences profitable?
MBX Biosciences, Inc. reported a net loss of $87.0 million for the fiscal year ended Dec 31, 2025, and used $79.9 million of cash in operations, per its annual report to the SEC.
How much does MBX Biosciences spend on research and development?
$79.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does MBX Biosciences have?
$418.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest MBX Biosciences (MBX) stock news?
Our latest story on MBX Biosciences, dated Sep 22, 2025: "MBX Biosciences files for 10,000,000-share offering, later sells 11,108,055 at $18.00". MBX Biosciences filed an S-1 on September 22, 2025 for 10,000,000 shares. The deal priced on September 24 at $18.00 for 11,108,055 shares and closed on September 26 with net proceeds of about $187.5 million. Source.
What is MBX Biosciences's market cap?
We do not publish live share prices. In its annual report, MBX Biosciences, Inc. put the market value of shares held by non-affiliates (public float) at $237.3 million as of Jun 30, 2025.
Investor discussion: MBX Biosciences
Members talk about MBX Biosciences (MBX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at MBX Biosciences, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Financings
Reported a financing. SEC Form 8-K (Items 8.01). Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:MBX on TradingView.
SEC filings and registration
SEC name
MBX Biosciences, Inc.
CIK
1776111
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
MBX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
11711 N. MERIDIAN STREET, CARMEL, IN, 46032
Phone
3179893100
Shares outstanding
48,160,096 as of 2026-08-03 (10-Q filed 2026-08-06)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
MBX Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MBX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio